Abstract:Nur77 (also known as TR3 and NGFI-B) is a nuclear orphan receptor that in response to various stimuli can translocate from the nucleus to the mitochondria, bind Bcl-2, and induce a conformational change in Bcl-2 that exposes its BH3 domain. This conformational change of Bcl-2 transforms this protein into a pro-apoptotic molecule that can induce cytochrome c release and apoptosis (Cell 116:527, 2004). Interestingly, in acute myeloid leukemia (AML) cell lines and blasts, Nur77 is absent. We have recently generated a nine amino acid peptide from the Nur77 protein (TR3) that is capable of inducing the same pro-apoptotic conformational change in Bcl-2 that Nur77 elicits (manuscript submitted). We tested the hypothesis that a cell-permeable version of this peptide can induce Bcl-2-dependent apoptosis in AML cells and AML stem cells. Primary AML samples (n=6) were incubated with 20 μM control or TR3 peptide for 24 hrs. Induction of apoptosis was measured as CD34+38−123+ PS/Annexin V+ by multiparametric flow cytometry. Our results demonstrate that the L-enantiomer form of TR3 indeed induces apoptosis in total AML cells (60%, p=0.001) and CD34+38−123+ stem cells (67%, p=0.001), as compared to control peptide. Bax expression did not affect the peptide's ability to induce apoptosis, as wild-type HCT116 cells and HCT116 cells deficient in Bax showed similar levels of apoptosis after treatment with the TR3 peptide. However, Bcl-2 expression was shown to be critical since lentiviral shRNA ablation of Bcl-2 in KG1 cells completely prevented induction of apoptosis by TR3 peptides. We conclude that the TR3 peptide is a potent inducer of apoptosis that mimics the action of Nur77 on Bcl-2 at the mitochondrial level. These results suggest that the Nur77 peptide or compounds that mimic this peptide may have utility as a novel therapeutic agent against Bcl-2 expressing cancers and leukemias.

Nur77 Converts Phenotype of Bcl-B, an Antiapoptotic Protein Expressed in Plasma Cells and Myeloma

Biophysical Mechanism of Converting Apoptosis Regulator Bcl-2 from A Protector to A Killer in Cancer Cells by A Short Nur77-Derived Peptide

Orphan Nuclear Receptor Tr3 (nur77) Binds and Converts the Phenotype of Bcl-B an Anti-Apoptotic Bcl-2-Family Protein Predominantly Expressed in Human Plasma Cells.

A Novel Peptide Containing a Nine Amino Acid Sequence from Nur77 Induces Bcl-2-Dependent Apoptosis in AML.

A Role for the Orphan Steroid Receptor Nur77 in Apoptosis Accompanying Antigen-Induced Negative Selection.

Functional Redundancy of the Nur 77 and Nor-1 Orphan Steroid Receptors in T-cell Apoptosis

Induction of Apoptosis and Suppression of Tumor Growth by Nur77-derived Bcl-2 Converting Peptide in Chemoresistant Lung Cancer Cells.

Targeting Nur77 Translocation.

Phase Separation of Nur77 Mediates XS561-induced Apoptosis by Promoting the Formation of Nur77/Bcl-2 Condensates

Nur77 Links Chronic Antigen Stimulation to B Cell Tolerance by Restricting the Survival of Self-Reactive B Cells in the Periphery

Thymic Expression of the Transcription Factor Nur77 Rescues the T Cell But Not the B Cell Abnormality of <i>gld/gld</i> Mice

Thymic Expression Of The Transcription Factor Nur77 Rescues The T Cell But Not The B Cell Abnormality Of Gld/Gld Mice

PKA/Smurf1 signaling-mediated stabilization of Nur77 is required for anticancer drug cisplatin-induced apoptosis

Dual roles of orphan nuclear receptor TR3/Nur77/NGFI-B in mediating cell survival and apoptosis.

Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia

BI1071, a novel Nur77 modulator, induces apoptosis of cancer cells by activating the Nur77-Bcl-2 apoptotic pathway.

Modulation Of The Nur77-Bcl-2 Apoptotic Pathway By P38 Alpha Mapk

Bcl-2 Plays A Critical Role In Growth And In Spontaneous Or Induced Apoptosis In Myeloma Cell Lines: A Study With Inducible Bcl-2 Transfection Constructs

Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B

Heterodimerization with Bax is Required for Bcl-2 to Repress Cell Death.

Exploiting the Tr3 Interaction with Bcl-2 As A Novel Therapeutic Strategy of Cancer and Leukemia Therapy.